HMGB1 and neoplasm: In this study, increased cell-surface CRT expression and release of HMGB1 from the cell nucleus into the extracellular space indicated that 131I-hu4G4 therapy against gliomas elicited glioma cell ICD, which enhanced the tumor immunogenicity.